
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Studies of the atopic triad not only show an association between atopic dermatitis, allergic rhinitis, and asthma, but also show an increase in the prevalence among pediatric patients.